Dr Alex LUGOVSKOY (PhD in Biophysics) – Author of the Patent for MM141
Dr Alex Lugovskoy has joined Atlas Venture as Entrepreneur-in-Residence in January 2022. He has co-founded and leads Diagonal Therapeutics, a company that aims to capitalize on untapped opportunities for antibody receptor agonists as drugs. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts and an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.